Intertek leads the way as FTSE buoyed by data – London Report October 29, 2014 BRITAIN’S top equity index yesterday rose to its highest level in nearly three weeks on the expectation that the US Federal Reserve would signal that it was in no rush to raise interest rates. However, late last night – after the London close – investors elsewhere in the world were betting that a US rate [...]
Wall St slips as US Fed ends bond buying – New York Report October 29, 2014 US STOCKS closed with slight losses yesterday, finishing off their lows of the session, after the Federal Reserve ended its stimulative monthly bond-buying programme and expressed confidence in American economic prospects. In a statement after a two-day meeting, the Fed ended its quantitative easing programme of bond purchases, as had been expected. At its peak, [...]
Halloween 2014: Horror video games fit for fright night October 29, 2014 Why bother dressing up as a sexy nurse when you can lock yourself in your room and scare the living daylights out of yourself with these next-gen horror games… DEAD RISING 3 Xbox One, PC The latest incarnation of the zombie beat ‘em up sees you face off against hordes of the lumbering undead [...]
Why RBC left Alibaba deal October 28, 2014 ROYAL Bank of Canada pulled out of and forfeited fees in the Alibaba initial public offering (IPO), after an employee commented on the deal during the quiet period before the world’s largest IPO, it said yesterday. “An employee unrelated to the Alibaba IPO process inadvertently made a comment about the transaction on an industry webinar [...]
Poor US sales of diabetes drug hits Sanofi stock October 28, 2014 STIFF competition saw group sales at Paris-based drug manufacturer Sanofi rise at a lower than expected 5.1 per cent during the last quarter. The disappointing result sent Sanofi’s shares tumbling 10.64 per cent yesterday to close at €74.53 in Paris. Despite the slowdown and disappointing forecast for next year, Sanofi reiterated its ability to hit [...]
Epistem rises on successful test trials for tuberculosis treatment October 28, 2014 DIAGNOSTICS firm Epistem Holdings announced yesterday that a trial of its drug for tuberculosis, Genedrive, was successfully completed in India. The good news was mitigated by mixed annual results for the year to June that were also released yesterday, showing widening losses that increased to £2.3m from £1.5m in 2013, despite an increase in revenue [...]
Best of the Brokers for 29 October 2014 October 28, 2014 To appear in Best of the Brokers, email your research to notes@cityam.com PETRA DIAMONDS Barclays Equity Research reiterated its “overweight” rating despite seasonally weak demand in the diamond industry. The broker maintained its 12-month price target of 290p for Petra and stated that it expected demand to firm up and management to maintain its price [...]
FTSE held back by poor bank results but index still rises – London Report October 28, 2014 BRITAIN’S top equity index yesterday rebounded, helped by stronger mining stocks which offset a fall in banking shares such as Standard Chartered and Lloyds. The blue chip FTSE 100 index closed up by 0.6 per cent, or 38.71 points, at 6,402.17 points, bouncing back from a 0.4 per cent fall on Monday. Standard Chartered slumped [...]
Wall St lifts on better outlook – New York Report October 28, 2014 US SHARES rose more than one per cent yesterday, with the S&P 500 ending above its 50-day moving average for the first time in almost a month as strong earnings eased concerns about the outlook for corporate America. The Dow Jones industrial average rose 187.81 points, or 1.12 per cent, to 17,005.75; the S&P 500 [...]
A second look at portfolio risk: Are you really playing it safe? October 28, 2014 I’VE NEVER been a fan of the “best buy” lists published by the major fund platforms. But I always find it interesting to see what is attracting the hard-earned savings of private investors. The best-selling funds lists for September reveal the usual suspects: UK equity income, emerging markets and a couple of specific sector funds [...]
